Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
Inozyme Pharma, Inc. (INZY) is a clinical-stage biopharmaceutical company pioneering enzyme replacement therapies for rare mineralization disorders. This page provides investors and healthcare stakeholders with essential updates on INZY's progress in addressing conditions like ENPP1 Deficiency and calciphylaxis through its lead candidate INZ-701.
Access consolidated news about clinical trial developments, regulatory milestones, and scientific advancements. Our repository includes press releases on study results, partnership announcements with research organizations, and analyses of INZY's therapeutic approach targeting the PPi-Adenosine pathway.
Key updates cover safety/efficacy data from ongoing trials, manufacturing collaborations, and presentations at medical conferences. Bookmark this page to efficiently track INZY's progress in developing treatments for diseases with significant unmet needs.
Inozyme Pharma (Nasdaq: INZY) announced the appointment of Gayle Gironda as senior vice president of human resources. With over 20 years of experience, her background in organizational design and talent management will support the company’s transition to a clinical-stage operation. Gironda previously held key HR roles at Bristol Myers Squibb and Alexion Pharmaceuticals. The leadership highlights a commitment to fostering a collaborative culture focused on treating rare diseases, as the company aims to develop innovative therapies for conditions related to abnormal mineralization.
Inozyme Pharma announced the acceptance of its Clinical Trial Application (CTA) for INZ-701 to begin a Phase 1/2 trial targeting ABCC6 Deficiency. This milestone is part of the ANSM's Fast Track procedure. ABCC6 Deficiency is a rare, inherited disorder leading to severe calcification, affecting over 67,000 people globally. INZ-701 aims to restore plasma pyrophosphate (PPi) levels, crucial for preventing harmful calcification. The trial is set to start in mid-2021, with preliminary safety data expected by year-end.
Inozyme Pharma reported Q1 2021 financial results, highlighting a net loss of $11.1 million, or $0.47 per share. The company maintains a solid cash position with $147.6 million, expected to support operations until Q4 2022. Inozyme filed a Clinical Trial Application for INZ-701 targeting ABCC6 Deficiency, aiming to start a Phase 1/2 trial in mid-2021. Recently published preclinical data in the Journal of Bone and Mineral Research showcases INZ-701’s potential for treating ENPP1 Deficiency. The company presented findings from a Burden of Illness Study, marking significant progression in its clinical development strategy.
Inozyme Pharma presented preclinical data at the European Calcified Tissue Society Congress, indicating that INZ-701, an enzyme replacement therapy, successfully increased plasma pyrophosphate (PPi) levels and reduced calcification in an animal model of ABCC6 Deficiency.
This is significant as ABCC6 Deficiency, associated with Pseudoxanthoma Elasticum (PXE), currently has no approved treatments. Results showed a 68% to 74% reduction in calcification, highlighting INZ-701’s potential to address this rare disease affecting over 67,000 individuals globally.
Inozyme Pharma, a biopharmaceutical company focused on rare diseases, announced that CEO Axel Bolte will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on May 13 at 11:45 a.m. ET. The event will be available via live webcast on Inozyme’s website, with a replay accessible for 90 days post-event. Inozyme develops innovative therapeutics targeting diseases caused by abnormal mineralization, specifically focusing on ENPP1 and ABCC6 Deficiencies. The company aims to address the underlying causes of these rare genetic conditions.
Inozyme Pharma announced promising preclinical results for its lead candidate, INZ-701, in treating ENPP1 Deficiency. Peer-reviewed findings in the Journal of Bone and Mineral Research revealed that INZ-701 increased plasma levels of pyrophosphate (PPi), improved several disease markers, and reduced mortality in ENPP1-deficient mice. Key results include a dose-dependent increase in PPi levels and prevention of ectopic calcification. Inozyme plans to initiate Phase 1/2 clinical trials for ENPP1 Deficiency in mid-2021, strengthening INZ-701's potential as a therapeutic option.
Inozyme Pharma (Nasdaq: INZY) announced the presentation of preclinical data on INZ-701, targeting ABCC6 Deficiency/Pseudoxanthoma elasticum (PXE), at two upcoming conferences. The first, at the Society for Investigative Dermatology 2021 Virtual Meeting on May 5, focuses on preventing ectopic mineralization in a mouse model. The second presentation is at the European Calcified Tissue Society 2021 Digital Congress on May 7, highlighting INZ-701's efficacy as a recombinant ENPP1-Fc protein. The company is developing therapeutics for rare diseases related to abnormal mineralization.
Inozyme Pharma presented new data revealing the significant disease burden of ENPP1 and ABCC6 Deficiencies at the ACMG annual meeting. The study showcased how these rare genetic diseases impact patients differently across age groups, highlighting severe symptoms such as cardiac issues and skeletal abnormalities. The research included responses from 38 patients across nine countries, emphasizing the need for improved diagnosis and management strategies. Inozyme is preparing to start Phase 1/2 trials for its therapy INZ-701 targeting these disorders in 2021.
Inozyme Pharma (Nasdaq: INZY) announced the presentation of a study on the burden of illness associated with infantile onset ABCC6 and ENPP1 deficiency at the ACMG Annual Clinical Genetics Meeting from April 13-16, 2021. The poster titled 'From the Voice of Patients and Caregivers: Burden of Illness in Infantile Onset ABCC6 and ENPP1 Deficiency' will be displayed starting April 14, 2021. The research focuses on these rare diseases affecting mineralization pathways. The results will be available on Inozyme’s website post-conference.
Inozyme Pharma has announced changes to its Scientific Advisory Board (SAB), welcoming three experts in vascular calcification and renal disease: W Charles O’Neill IV, Jouni Uitto, and Paul B. Yu. David Thompson, former Chief Scientific Officer, joins the SAB as well. The transition follows the departure of three members, aiming to strengthen the company's focus on rare diseases linked to mineralization abnormalities. The new appointees bring valuable expertise that will aid Inozyme in its research and development efforts.
